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Abstract
Platelet-rich plasma (PRP) was mixed with thrombin and excess calcium result-
ing in activated platelets trapped within the fibrin network; within the matrix, 
platelets secrete bioactive substances that diffuse into the surroundings tissues. PRP 
is prepared from the patient’s own blood, a variety of manufacturing techniques in 
vastly different cell counts, and growth factor concentrations. The clinical use of 
PRP is treatment of soft tissue diseases and injuries, treatment of burns, hard-to-
heal wounds, tissue engineering, and implantology in dentistry. An essential crite-
rion for PRP is for it to be autologous, for the donor of the blood, and the recipient 
of the PRP to the same person. Most of the literatures suggest that PRP does not 
appreciably impact bone healing or induce bone formation. PRP might augment 
recruitment of osteoblast progenitors to injection sites or in sites expected to expe-
rience delayed healing. In this capacity, PRP might be utilized to initiate repair of an 
otherwise poorly healing bony lesion. PRP stimulates bone repair in fractures. Early 
through late healing process is compromised with fractures, including reduced cell 
proliferation, delayed chondrogenesis, and decreased biomechanical properties. In 
this chapter, the importance of the PRP in oral and maxillofacial surgery in trauma 
patients is studied
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1. Introduction
Today, regenerative therapy is the most preferred treatment because it is a 
method that meets the expectations of the patient close to the ideal. With the prog-
ress of technology, new materials about growth factors are entering our lives. Tissue 
engineering is currently working hard to develop regenerative materials. The health 
sector and tissue engineering benefit from each other in this respect.
First-generation platelet concentrate platelet-rich plasma (PRP) was used as 
a biomaterial to speed up the process of healing of the tissues. PRP contains high 
concentrations of platelets and growth factors in the low-volume plasma. These 
growth factors stimulate cell proliferation, matrix formation, and angiogenesis [1].
In 2001, platelet-rich fibrin (PRF), a second-generation platelet concentrate 
product, was developed in France, which was first developed for use in oral and 
maxillofacial surgery [2]. PRF preparation technique is based on the principle of 
collecting platelets and growth factors in the fibrin matrix by centrifuging venous 
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blood from the patient. There are many forms of PRF materials such as P-PRF, 
L-PRF, A-PRF, I-PRF, and T-PRF used in oral and maxillofacial surgery.
2. Platelets
Platelets are cytoplasmic fragments of mature megakaryocytes in bone mar-
row. They are responsible for tissue regeneration by clotting, at the onset of wound 
healing, and by growth factors released from alpha granules. They are isolated from 
peripheral blood vessels [3].
Because of their short lifespan, the megakaryocytes should produce about 
1.5–4 × 1010 platelets per day to keep the platelet count in the normal blood count 
at 1.5–4.5 × 105 per microlitre (μL) of blood [4].
In 1960s, the interaction between platelets and endothelial cells supporting capil-
lary endothelin integrity was revealed [5, 6]. Initial work by Folkman and colleagues 
used autologous PRP-augmented media to feed microvascular endothelial cells to 
enhance vascular integrity preservation in organs subjected to perfusion for trans-
plantation. It has been determined that human platelet lysate (HPL) was prepared 
by repeated freezing/thawing cycles throughout the 1980s, and cell lines and primer 
fibroblasts were promoted by fresh blood or old platelet concentrates [7–9].
Platelets are quite active in terms of metabolism. Growth factors were released by 
platelet function with the phenomenon of “activation of macrophages by an increase 
in connective tissue healing, bone regeneration and repair, mitogenesis of fibro-
blasts, and angiogenesis of the wound area” by stimulating cell proliferation [10, 11].
After the resulting tissue damage, the platelets appear and the basal membrane 
of the collagen capillaries and the subendothelial microfibrils directly change shape. 
The alpha granules in the platelets engage the cell plasma membrane and release 
protein contents around with activation [11].
If the defects are small, platelet clotting is sufficient, and large wounds may 
require blood clots. The blood clot is activated from intrinsic and extrinsic pathways. 
“Intrinsic pathway” begins when there is a change in tissue damage or in blood. The 
“extrinsic pathway” begins with blood contact with factors other than blood, such 
as damaged tissue. Although they start differently in two ways, they converge on the 
next steps and share the reaction series. Coagulation in the presence of calcium and 
thrombin occurs by fibrinogen polymerization of fibrinogen monomers. The fibrin 
clot also provides a matrix environment for migration of fibroblasts and other tissue-
forming cells, including endothelial cells, other than hemostasis [12].
3. Wound healing
Wound healing is a complex but a controlled mechanism regulated by growth 
factors and extracellular matrix.
Healing stages are:
1. hemostasis,
2. inflammation,
3. proliferation (granulation and contraction), and
4. remodeling (maturation) [13].
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3.1 Hemostasis
Platelets behave like workers who close the damaged gas and water lines and seal 
damaged blood vessels. Blood vessels react to injury by vasoconstriction, but this spasm 
ends loosely. Thrombocytes secrete vasoconstrictor substances to facilitate this process, 
but this is not the main role. The primary role of platelets is to form clots. Adenosine 
diphosphate (ADP) leaks from damaged tissues. Platelets adhering to type 1 collagen, 
which is activated by ADP, thus become active. They are viscous glycoproteins that 
secrete and cause platelet aggregation [14]. At the same time, thrombocytes secrete 
factors that interact with and stimulate intracellular coagulation by intrinsic thrombin 
production, which initiates fibrinogen to fibrin. Platelets also secrete platelet-derived 
growth factors, known as one of the initiating factors for the healing process.
3.2 Inflammation
Inflammation is clinically associated with pain, swelling, temperature, and 
erythema, occurring between the first and fourth days after injury. Neutrophils 
perform their first defense against infection by phagocytosing existing debris and 
microorganisms. When the neutrophils digest bacteria and debris, they complete 
their task and die.
In wound repair, communication between soluble proteins and cells is ensured. 
These soluble proteins are growth factors and cytokines released by the cell. The 
role of the extracellular matrix in wound healing is activation of platelets, epithelial 
migration, and interaction with cells through receptors called integrins that lead to 
the movement of fibroblasts [15].
Macrophages secrete bacterial phagocytes and extracellular enzymes, to break 
down necrotic tissues and form the second line of defense. Secreted extracellular 
enzymes and matrix metalloproteinases (MMP) are calcium and zinc sources for the 
active site. MMP is responsible for necrotic tissue removal and repair of damaged 
tissue. MMP metalloproteinases are inactivated by tissue inhibitors (TIMPs) and 
uncontrolled activities are counterbalanced. Macrophages, fibroblast growth factor, 
epidermal growth factor, transforming growth factor-beta (TGF-β) and interleukin 1, 
etc. stimulate proliferation by secretion of cytokines and growth factors [16].
3.3 Proliferation
Proliferation begins after the injury of tissues and continues until the size of the 
wound and the systemic condition of the patient is up to 21 days in acute injuries. 
Characteristically, “angiogenesis,” “collagen deposition,” “granulation tissue” 
formation, “wound contraction,” and “epithelialization” are seen at this stage.
Cells are introduced into the proliferation phase: macrophages, fibroblasts, 
pericytes, endothelial cells, and keratinocytes.
Fibroblasts are responsible for the secretion of collagen. In case of a damaged 
home, “plumber” cells are pericytes that renew outer layers of capillaries and 
endothelial cells that “glue.” This process is called angiogenesis. Keratinocytes play 
the role of “roof plumber” and are responsible for epithelization.
3.4 Remodeling
Similarly, collagen tissue must be rearranged to provide greater tensile strength 
in wound repair. In addition, the density of cells and capillaries is reduced. The 
Trauma in Dentistry
4
main cells involved in this process are fibroblasts. Remodeling can last up to 2 years 
after wounding [17].
4. Three therapeutic improvements through the wound healing 
mechanism: primary, secondary, and tertiary healing
4.1 Primary wound healing
Primary wound healing is called healing if the cleaved cleft is closed without any 
complications. Within 24 h, the minimal space existing between them is filled with 
fibrin and makes fibrinous adhesion.
4.2 Secondary wound healing
The healing form of granulation tissue in open wounds is called “secondary 
wound healing.” Initially wounded with clots and exudates, the wound is filled 
by fibroblasts 4–5 days after injury. In this type of healing, the wound surface is 
covered with scar tissue after 30–40 days following injury.
4.3 Tertiary wound healing
In case of infection, in the over-devitalized tissues and in the presence of a 
foreign body, the improvement observed by closing the wound after a few days is 
called “delayed primary healing” (tertiary wound healing).
5. Platelet-rich plasma (PRP)
Platelet-rich plasma (PRP) was first developed in the early 1970s, but it was used 
rarely. PRP was mixed with thrombin and excess calcium resulting in activated 
platelets trapped within the fibrin network; within the matrix, platelets secrete 
bioactive substances that slowly diffuse into the surroundings tissues. PRP was 
introduced to the dental community by Whitman and colleagues, who hypothesized 
that the activation of platelets and the subsequent release of growth factors would 
enhance surgical healing [10]. PRP is now commonly applied to surgical sites and 
injuries to promote wound healing. PRP is rich in growth factors  (PRGF), platelet-
rich fibrin matrix (PRFM), and platelet-rich fibrin (PRF) [18].
The natural blood clot contains 95% of red blood cells, 5% of platelets, and 1% 
of white blood cells; thrombocyte-rich plasma obtained by centrifugation of blood 
tissue contains 4% of red blood cells, 95% of platelets, and 1% of white blood cells. 
Platelet concentrates in plasma are called “platelet-rich plasma.” The goal of using 
platelet-rich plasma is to accelerate healing. High levels of platelets and growth 
factors also include all components of clotting factors. At least 5 ml of plasma is 
required for platelet-rich plasma to be clinically effective in order to have 106 μl 
of platelets. The platelet-rich plasma should be prepared in nonclotted form and 
should be used within 10 min from the start of coagulation [19, 20].
“Platelet-rich plasma” is administered by “injection” to the site of interest or by 
mixing with “grafts.” “Platelet-rich plasma” has a long storage period, but should be 
used quickly when used. It takes up to 7 days in the region where the growth factors 
are applied [21].
1. Preparation of platelet-rich plasma
Nowadays, there are many preparation methods. These are as follows:
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a. Preparation with standard blood bank procedures:
• It can be prepared in Aferez units
• It can be prepared from whole blood donors
2. It can be prepared with the aid of a test tube with 20–60 cc of blood.
3. It can be prepared using commercially available automatic preparation devices 
[22, 23].
4. PRP is subjected to a process known as differential centrifugation. It is pre-
pared clinically by “PRP method” or “buffy coat method” [22, 23].
In the PRP method, an initial centrifuge (3000 rpm for 3 min) at low speed 
separates red blood cells (RBC), and then a second centrifuge (4000 rpm for 3 
min) is applied at high speed to concentrate the platelets. In the initial centrifuge, 
the venous blood is centrifuged in tubes containing citrate dextrose. Acid citrate 
dextrose is an anticoagulant agent.
After the initial centrifugation, the whole blood is divided into three layers:
1. A top layer (platelet poor plasma) containing mostly “platelets” and “white 
blood cells (WBCs)” is of 40%.
2. An intermediate layer is rich in white blood cells known as the buffy coat and is of 5%.
3. A lower layer consisting mostly “red blood cells” is of 55% [23].
For the production of pure PRP (P-PRP), the top layer and the cover of the 
intermediate layer known as the buffy coat are transferred into an empty sterile 
tube. For the production of leucocyte-rich PRP (L-PRP), the top layer known as 
“PPP” is transferred to the entire layer of the “buffy coat” and a few “red blood 
cells.” By the second centrifuge, the “red blood cells” and the PRP are separated. 
The PRP obtained after the second centrifugation is activated with thrombin and 
calcium chloride to prepare a PRP gel. PRP gel contains high amounts of platelets 
and natural fibrinogen. It takes approximately 30 min to prepare PRP with this 
technique. Prepared PRP should be used within 6 h.
6. Things to be aware of when preparing PRP
• In acid citrate dextrose (ACD-A), tubes should be obtained with whole blood by 
venipuncture.
• Blood should not be chilled at any time before platelet separation or platelet 
separation.
• Whole blood must first be centrifuged at “low speed.”
• Supernatant containing platelets (floating on top of the precipitate) should be 
transferred into another sterile tube (no anticoagulant).
• Tube should be centrifuged at a higher speed (hard spin) to obtain platelet 
concentrate.
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• At the end of centrifugation, bottom 1/3 of the tube consists of PRP and the 
top 2/3 consists of PPP. At the bottom of the tube platelet, pellets are observed.
• It is necessary to suspend platelet pellets in a minimum amount of plasma (2–4 ml) 
by removing the PPP and gently shaking the tube [24, 25].
There are also several factors that influence platelet concentration, such as the 
size of the platelets, the biological differences between individuals, and the hema-
tocrit variability. It is more critical after the second centrifuge because the process 
of separating red blood cells intended for the first centrifugation may not be fully 
realized and erythrocytes may be present in the transferred volume. The remain-
ing erythrocytes form a pellet at the base of the tube. Approximately, 20% of the 
platelets remain adsorbed on erythrocyte globules [26].
Another issue to be aware of is the impossibility of obtaining platelet-rich plasma 
from a non-anticoagulated blood. Platelets are responsible for the initiation of hemo-
stasis and healing. Since platelets do not have platelets in the serum, it is not possible to 
obtain platelet-rich plasma from the serum, only anticoagulant platelets are possible.
Clinically, acid citrate dextrose or citrate phosphate dextrose is frequently used 
for anticoagulation. Citrate phosphate dextrose, acid citrate dextrose, has similar 
properties but has been suggested to be 10% less effective in protecting throm-
bocyte vitalites in studies. EDTA is not recommended because it will damage the 
platelet membrane.
Dual centrifugation technique is necessary to prepare platelet-rich plasma. Not 
enough platelets can be obtained with a single centrifugation and a mixture of both 
platelet-rich plasma and thrombocyte poor plasma cannot be separated completely [26].
7. Mechanism of action of platelet-rich plasma
Growth factors alone do not increase bone production. Platelets increase in the 
area applied with platelet-rich plasma. The increase in platelets also increases the 
growth factors numerically. PRP also contributes to bone regeneration by increasing 
the number of stem cells in a small number. Marx used a combination of bone graft 
and platelet-rich plasma in mandibular defects and attributed the contribution of 
platelet-rich plasma to bone regeneration to the function of growth factors in the 
environment [27].
Platelet-rich plasma is the basis for the activation of defense mechanisms by the 
activation of macrophages and the formation of a nonspecific immunoreaction with 
the leukocytes and interleukins involved.
The platelet-rich plasma has antimicrobial properties against microorgan-
isms such as “Escherichia coli,” “Staphylococcus aureus,” “Candida albicans,” and 
“Cryptococcus neoformans” [28].
8. Duration of action and storage of platelet-rich plasma
The duration of action of PDGF and TGF-β in the platelet-rich plasma was investi-
gated and a reduction in cell growth stimulating activity between 4 h and 3 days after 
venous blood ingestion was reported [29]. It is recommended to use PRP within the 
first 6 h after its preparation to keep the prepared biomaterials at a minimum level of 
contamination and to minimize disease transmission risks [30, 31]. It has been suggested 
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that the degranulation of platelets and the release of growth factors are within the first 
3–5 days; therefore, the effect of platelet-rich plasma is also 7–10 days [32]. Although the 
direct effects of platelets and growth factors are lost, bone regeneration is expected to 
continue, since the lifespan of active osteoblasts is approximately 3 months [33, 34].
9. Classification of platelet-derived blood concentrates
9.1 Pure platelet-rich plasma (P-PRP)
Using only the upper part of the yellowish layer to inhibit the presence of leuko-
cytes, resulting biomaterial leads to a lower platelet count. Because it is possible to 
prepare clinically, it is a low-cost application [33, 35].
9.2 Leukocyte and platelet-rich plasma (L-PRP)
Blood in sterile tube containing no anticoagulants is subjected to initial centrifuga-
tion. All of the poor plasma and buffy coat layers from the cell and a portion of the bot-
tom layer containing the red blood cells are transferred to a new tube. At a high speed, a 
second centrifugation is carried out and the poor plasma layer from the cell is withdrawn 
by pipetting. Coagulation is achieved by adding thrombin or calcium chloride as the 
activator. L-PRP, which takes time to prepare by hand, also has low density [35].
9.3 Pure platelet-rich fibrin (S-PRF)
The “P-PRP,” “L-PRP,” and “P-PRF” biomaterials all contain too much tombo-
cytes from physiological values. It is reported in the literature that biomaterials 
with platelet content 2.5 times more than the number of platelets present are most 
effective [36].
9.4 Leukocyte and platelet-rich fibrin (Choukroun’s PRF) (L-PRF)
L-PRF is a platelet concentrate containing all components of blood. There is 
no need for any anticoagulant agents in the preparation of L-PRF, so it can be 
regarded as a second-generation platelet concentrate. It is used in oral, maxillofa-
cial, otorhinolaryngology, and plastic surgery. In the technique of preparing L-PRF, 
platelets and leukocytes are obtained with high efficiency. With the activation of 
L-thrombocytes, thrombocyte and leukocyte growth factors are embedded in the 
fibrin matrix [37–44]. In the biomaterial prepared, leukocytes act as an infection-
preventive cells and immunomodulator [45, 46].
9.5 Advanced platelet-rich fibrin (A-PRF)
For L-PRF preparation, centrifugation for 12 min at a speed of 2700 rpm is 
required, but at a slower speed such as 1500 rpm for A-PRF preparation, longer 
time such as 14 min is required. Studies have shown that the number of viable cells, 
including platelets, is higher in A-PRF. Clinically, it will be beneficial for increasing 
amounts of growth factor and cytokine release. Reported that the levels of growth 
factors (TGF, PDGF-AB, VEGF) released from A-PRF are less than those of L-PRF 
when compared to that of L-PRF [47].
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9.6 Injectable platelet-rich fibrin (I-PRF)
One of the latest developments in PRF technology is the production of injectable 
PRF (I-PRF). For preparation of I-PRF, blood samples are taken in plastic tube without 
anticoagulant and centrifuged at 2400–2700 rpm at about 700°C for 2–3 min [48].
9.7 Titanium platelet-rich fibrin (T-PRF)
During PRF preparation, different products are obtained using different materials 
for blood processing. Medical titanium tubes to produce PRF and 111333, named this 
material T-PRF [49]. In one study, it was observed that T-PRF samples had a fairly 
regular network than L-PRF samples [49]. In addition, the T-PRF fibrin network 
was observed to cover the wider area of the L-PRF fibrin network and the fibrin was 
thicker in the T-PRF specimens. T-PRF was obtained by centrifugation of 20 ml of 
blood at 2800 rpm for 12 min in medical titanium tubes in a human study. T-PRF 
membranes were found to have positive effects on palatal mucosal wound healing [49].
9.8 Concentrated growth factor (CGF)
The most important different CD34 stem cell content from the thrombo-
cyte-rich plasma and fibrin of the concentrated growth factor is the content. 
CGF-CD34 is the name of the layer containing platelets, leukocytes, growth 
factors, and cytokines by separating the autologous blood into its components 
by centrifugation at four different rpm at the same time. Concentrated growth 
factor does not cause any infection or immunological reaction as it is prepared 
from the own blood of the person, and no chemicals are used during the pro-
cess. CGF causes less inflammation, bleeding, and pain than other materials. 
Due to the stem cell content of CD34, regeneration capacity is higher than other 
biomaterials [50].
10. In vitro applications of thrombocyte-rich plasma
Although the clinical use of PRP and PRF is widespread in oral and maxillofacial 
surgery, the mechanism of cellular action has not yet been clearly elucidated. Although 
in vitro studies have been carried out on dental-derived cells, there is no comprehen-
sive study describing the mechanism of action of stem cells. A limited number of 
in vitro studies do not provide a convenient and reliable basis for clinical practice.
Thrombin-activated plasma stimulate “adhesion,” “migration,” and “myofibro-
blastic differentiation” of human gingival fibroblasts [51]. In another study, PPP 
and 50% PRP resulted in the greatest increase in cellular proliferation and differ-
entiation at various concentrations, the proliferation of osteoblast and periodontal 
connective tissue cells in platelet-rich plasma and platelet-poor plasma, and the 
effect on calcium formation [52].
Functions of the platelet-rich plasma are obtained from periodontal ligament 
tissue and pulp of human tooth root cells [53]. Colony formation and cellular 
proliferation of dental cells reduced platelet-rich plasma at concentrations of 0.5 
and 1% [53].
Thrombocyte-rich fibrin regulates cell proliferation in a cell-type-specific man-
ner, and that the thrombocyte-rich fibrin can promote cell proliferation [54].
In vitro studies of “platelet-rich plasma” have shown that the “PDGF-AB” and 
“TGF-β” factors are in high concentrations in platelet-rich plasma preparations 
and that the platelet—the proliferation [55, 56]. In another study of the same 
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researchers, it was observed that the fibrinogen used with growth factors in plate-
let-rich plasma effectively increased wound healing in periodontal tissues.
11. Clinical studies on platelet-rich plasma
Contrary to in vitro studies, there is extensive literature in clinical trials. 
Thrombocyte-rich plasma in dentistry is used to increase tissue regeneration in 
periodontal disease, to accelerate healing of alveolar plugs after tooth extraction, 
and to accelerate osseointegration around dental implants [48, 56, 57].
First time, 88 mandibular bone defects were treated with autogenous bone graft, 
some with autogenous bone graft, and some with platelet-rich plasma. As a result 
of the study, it was observed that platelet-rich plasma significantly increased bone 
regeneration [27]. After tooth extraction, many complications can occur. There are 
studies showing that the graft site is covered with thrombocyte-rich plasma and local 
conditions such as “dry socket” and “abscess” formation are prevented, and condi-
tions are improved. It has been reported that high aftertouch growth factor concen-
tration increases tissue regeneration [58–62]. There are also studies in the literature, 
which show conflicting results with other studies suggesting that the platelet-rich 
plasma administered after tooth extraction does not have a significant effect. There 
are also observations that thrombocyte-rich plasma does not increase bone regen-
eration alone, as is the case with osseointegration at dental implant placement and 
studies that give positive platelet-rich plasma to accelerate new bone formation.
There are reports of positive results associated with thrombocyte-rich fibrin 
in sinus augmentation therapy prior to placement of the dental implant [62–66]. 
Co-use of deproteinized bovine bone (Bio-Oss) and thrombocyte-rich fibrin is 
only compared with Bio-Oss use; combined use of maxillary bone atrophy has been 
reported to give better results [67, 68].
Contradictory results have also been observed in the use of platelet-rich plasma in 
periodontal surgery. There are studies reporting increased tissue regeneration when 
applied with platelet-rich plasma graft materials [68, 69] while some studies suggest no 
improvement in healing process after thrombocyte-rich plasma implantation [70, 71]. The 
same conflicting results exist in the literature for thrombocyte-rich fibrin. Thrombocyte-
rich fibrin in the third molar withdrawal of the mandible did not increase bone repair.
It has been demonstrated that the application of “thrombocyte-rich plasma” is 
effective in the “bison-linked osteonecrosis (BRONJ)” treatment of the jaw. The 
application of surgical debridement procedures in conjunction with autologous 
thrombocyte-rich plasma was reported that increased bone and soft tissue regen-
eration, increased neovascularization, and reduced tissue inflammation [71–76]. 
According to some investigators, thrombocyte-rich plasma regeneration capacity is 
a low biomaterial and may have a short-lived effect in the early phase of bone heal-
ing, flattening between the third and sixth months of treatment.
11.1 Use of platelet-rich plasma in surgical sockets
Thrombocyte-enriched plasma to the suction ports and stitch area of 170 
patients after withdrawal of third molar teeth and alveolar osteitis was prevented 
with less pain and more intense bone formation [48].
In 20 patients with “periodontal defect” and “vertical root fracture” in two 
groups as thrombocyte-rich plasma and autogenous bone graft applied, only 
autogenous bone graft was applied. As a result, epithelialization of the group with 
autogenous bone grafting with thrombocyte-rich plasma and bone healing was 
faster [77].
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11.2 Use of platelet-rich plasma in jaw reconstructions
“Autogenous bone graft” and “platelet-rich plasma” combination in “man-
dibular reconstruction” significantly improves bone healing [78]. Patients who 
underwent “partial mandibulectomy” combined “autogenous bone graft” and 
“thrombocyte-rich plasma” for reconstruction. After 6 months, they found that 
the biopsy bone they had received was sufficient and they applied the implant 
after 1 year [79].
11.3 Use of platelet-rich plasma in distraction osteogenesis
Implants in patients were done by injecting “mesenchymal stem cells” and “plate-
let-rich plasma” into the distraction range to obtain three-dimensional bones in the 
distraction osteogenesis of the mandible and to shorten the consolidation period. They 
reported that platelet-rich plasma was effective at the end of the study [80].
Injected mesenchymal stem cell and thrombocyte-rich plasma derived from 
bone marrow were used for “achondroplasia” and “congenital pseudoarthrosis. As a 
result of the study, they reported that short-term minimally invasive procedure is an 
advantage of increasing bone regeneration [81].
11.4 Use of platelet-rich plasma in individuals with alveolar cleft
Patients with alveolar congenital defects were using bone and tibia-derived 
grafts plus thrombocyte-rich plasma and reported that the corresponding region 
was rapidly restored according to the patient group, who had never used thrombo-
cyte-rich plasma [82].
Autogenous bone grafts, in five of 12 patients with alveolar cleft, and the 
remaining seven were combined with autogenous bone and thrombocyte-enriched 
plasma in the remaining seven and closed the scales. They reported that regen-
eration in patients who were closed by a combination of autogenous bone and 
thrombocyte-rich plasma in a computed tomography scan was better than the 
other group [83].
11.5 Use of thrombocyte-rich plasma in oriented bone regeneration technique
Lecovic et al. reported that the combination of thrombocyte-rich plasma and 
bovine peroneal bone mineral was effective in the treatment of intrabony defects 
in patients with chronic periodontitis, although no directed tissue regeneration was 
performed [84].
11.6 Use of platelet-rich plasma after peripheral nerve injury
Peripheral nerve injuries may occur after surgical operations in the maxillofacial 
region and after trauma to the maxillofacial region. “Microsutures,” “fibrin-
cyanoacrylate adhesives,” “grafting,” and “laser” applications are preferred in the 
treatment of injured nerve tissue. However, the regenerative capacity of the nerve 
tissue is limited and heals very slowly. The use of platelet-rich plasma was consid-
ered to speed up this process of healing. An animal study was conducted using rats, 
although there is no human study on the subject. After the sciatic nerves of the rats 
were cut bilaterally, the nerve was connected with “cyanoacrylate” on one side and 
“platelet-rich plasma” on the other side. The number of nerve fibers formed on the 
treated side of the biopsied platelet-rich plasma after 12 weeks was higher than the 
other side [85].
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11.7 Use of platelet-rich plasma in soft tissue injuries
Platelet-rich plasma is also effective in soft tissue injury as it is effective in hard 
tissue repair. Two groups were formed in the study in which 59 patients with acute 
traumatic soft tissue injury were treated. Thirty-two patients were treated with 
routine wound care while the remaining 27 patients were treated with routine 
thrombocyte-rich plasma as well as with routine wound healing. As a result, wound 
healing was faster in the platelet-rich plasma group [85].
12. Conclusion
Platelet-rich preparations are a safe (PRP) and is a preparation of plasma 
that contains an increased concentration of platelets compared to blood. PRP is 
autologous: for the recipient of the PRP to be the same person. PRP is used for both 
soft and hard tissue and also used in clinical dentistry, because it accelerates bone 
formation and induces healing.
Many studies support the use of autologous PRP in clinical practice, including 
for soft tissue injuries, chronic diabetic ulcers; injuries to muscles, tendons, or liga-
ments; bone fractures; molar extractions; urologic, dental, ophthalmic, and plastic 
surgery procedures; and periodontal, sinus lift, and oral/maxillofacial surgeries. 
Since growth factors play crucial roles in soft and hard tissue regeneration, the 
proposed mechanism for the enhanced healing outcomes by PRP is through the 
release of critical growth factors by activated platelets [86, 87].
Bone lesions and defects may arise out of many kinds of traumas. Due to the 
high prevalence of trauma, bone is the most transplanted tissue.
The use of autologous grafts is a gold standard to the biomaterial filling of bone 
defects. However, the limitation of tissue available, risks of infection, and necrosis 
re-motivated the proposition on synthetic biomaterials, which by turn are not 
biologically functional and adapted to remodeling bone tissue.
The use of biological factors, such as PRP and bone morphogenetic proteins (BMP), 
has shown good results in bone reconstructions, since they are directly associated with 
the tissues. Platelet growth factors such as platelet-derived growth factor (PDGF), 
transforming growth factor-b (TGF-b), fibroblast growth factor (FGF), vascular endo-
thelial growth factor (VEGF)-A, and insulin-like growth factor (IGF-1) regulate bone 
regeneration, proliferation, and differentiation of osteoblasts, for the therapeutic use.
The use of PRP in the treatment of bone lesions has shown significant results 
from 1990s. PRP also used as an alternative to fibrin glue or platelet gel is frequently 
employed in maxillofacial defects. The therapeutic benefits and the reparative 
power of PRP consist of one action faster than conventional treatments maximized 
by autologous growth factors and are free from immune complications.
PRP action with the concentration of bone marrow had better consolidation 
and greater bone quantity by area in the PRP group. The superior result obtained 
can be explained by the immediate recruitment of all proteins necessary to start the 
healing cascade, while the concentration of bone marrow demanded longer time 
to recruit these elements. Thus, it can be assumed that the monitoring for a period 
of time up to 4 weeks, this group might have had similar results of consolidation. 
However, there were no new studies that could confirm this hypothesis.
Several studies reporting the association of PRP and artificial bone grafts 
showed improvement in the quality of healing. However, only PRP was used, and 
the short-term and/or long-term results, were positive but not significant. PRP 
could be beneficial and contribute to the morphological and functional improve-
ment in chronic tendinopathy [86, 87].
Trauma in Dentistry
12
In treatment of tendinopathy, PRP plays an important role. Physical therapy and a 
program of activities after injection of PRP, adopted in most studies, demonstrate better 
results in tendon lesions [88].
Platelet-rich plasma is a blood-derived product used for local healing. Interest in 
their activity over the last two decades has increased significantly in different dis-
ciplines. It is widely accepted that these materials stimulate soft and hard tissues to 
mimic the physiological healing process. The reason is that it contains high amounts 
of blood components such as fibrinogen, platelets, etc.
These biomaterials have been proposed for various uses in oral and maxillofacial 
surgery. Most studies in the literature: improvement of alveolar sockets after shrink-
age, osseointegration of dental implants, sinus lifting procedures, improvement 
of periodontal bone defects, etc., examine the effects on the case. It has also been 
observed that platelet concentrations increase cell migration and neovascularization 
in vitro studies.
In addition to having many advantages of platelet-rich plasma, there are also 
disadvantages: increased risk of malign transformation as the PDGF release 
increases in chronic wounds, and the lack of factor V of the bovine thrombin used 
for anticoagulants and immunological reactions.
The activity of the platelet concentrates is expected with the high amounts of active 
growth factors and cytokines they contain. Nowadays, the preparation of these platelet 
concentrates is very different from each other. When platelet concentrates are com-
pared, thrombocyte-rich fibrin is thought to have a higher regenerative potential than 
thrombocyte-rich plasma.
Platelet-rich plasma is a blood-derived product used for local healing. Interest 
in their activity over the last two decades has increased significantly in different 
disciplines. It is widely accepted that these materials stimulate soft and hard tissues 
to mimic the physiological healing process. The reason is that fibrinogen contains 
high amounts of blood components such as platelets.
Bone defects caused by infection, tumor, trauma, metabolic disease, or massive 
osteolysis due to prosthesis still remain a major clinical concern. Unfortunately, the 
self-repair capacity of the critically bone defected is extremely limited and this condition 
generally requires bone grafting. Osteoinductivity, osteoconductivity, and osteogenesis 
are optimal bone graft substitute. Allografts or xenografts have unique osteoconductive 
properties and rarely cause disease transmission. Because of these limitations, synthetic 
bone grafts are being used. Osteoinductive growth factors, autogenic bone marrow, and 
mesenchymal root cells promote osteogenesis while demineralized bone matrix (DBM) 
and platelet-rich plasma (PRP) induce formation of progenitor cells from surrounding 
tissues. However, each of these substitutes has its own significant limitations and none of 
them meets full expectations to serve as bone substitute in instance of bone defect.
Both PRP and DBM are osteoinductive substitutes that have shown satisfactory 
results for fracture healing. A number of growth and differentiation factors are liber-
ated, including platelet-derived growth factor (PDGF), vascular endothelial growth 
factor (VEGF), transforming growth factor-1 (TGF-1), insulin-like growth factor-1 
(IGF-1), hepatocyte growth factor, platelet factor-4, fibroblast growth factor (FGF), 
trombospondin-1, osteonectin, and fibronectin via activation of platelets. These factors 
play an important role in intracellular matrix formation, osteoid production, and the 
collagen synthesis involved in fracture healing. DBM is an organic collagen matrix that 
includes various types of bone morphogenetic proteins (BMP), which are responsible 
for its osteoinductive properties. PRP can be prepared easily with two-step centrifuga-
tion of autogenous blood, and DBM can be obtained commercially.
Through positive impacts of PRP and DBM based on these findings, the pres-
ent study evaluated the impact of individual and combined applications of PRP 
and DBM on fracture healing of critical bone defects. Allogeneic PRP would 
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have beneficial effect on treatment of segmental bone defects, comparable to 
DBM. Possibility of agonistic or additive osteoinductive effects of DBM and PRP 
combination was also investigated [89].
Despite the large number of clinical trial studies, there is little evidence of the 
cellular effect of blood derivatives. The lack of standard protocols leads to the lack 
of reliable clinical results. Frequent and unnecessary application of blood-derived 
products, especially in the maxillofacial region, results in both an increase in proce-
dures and a significant increase in costs to clinicians and patients. The indications 
of the protocols for the application and preparation of blood derivatives should 
be made absolutely widespread and systematic in order to clarify the benefits for 
patients of blood derivatives. This can be achieved through a collaborative work 
between clinical and in vitro researchers. Further research on thrombocyte-rich 
plasma and thrombocyte-rich fibrin activity on dental cell biology, more clinical 
application of platelet concentrates, and greater use in the oral and maxillofacial 
region may provide a stable basis for more predictable outcomes.
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